ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo

This article was originally published here

“Based on the encouraging interim data Lonca and ibrutinib demonstrated in Phase 1, the trial was amended to a Phase 1/2 protocol intended to support the submission of

The post ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply